Stock QNRX QUOIN PHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.7079 USD +3.33% Intraday chart for Quoin Pharmaceuticals, Ltd. +7.26% -85.57%
Mar. 15 Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating MT
Mar. 14 Quoin Pharmaceuticals Seeks M&A Opportunities CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
AQ
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
AQ
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
AQ
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
AQ
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
AQ
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
AQ
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
AQ
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
AQ
Quoin Pharmaceuticals : Modification to Rights of Security Holders - Form 8-K
PU
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
AQ
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
AQ
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
AQ
Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET
AQ
Quoin Pharmaceuticals : Modification to Rights of Security Holders - Form 8-K
PU
Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
AQ
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
AQ
Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET
AQ
QUOIN PHARMACEUTICALS, LTD. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial
AQ
QUOIN PHARMACEUTICALS, LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QNRX Stock
  4. News Quoin Pharmaceuticals, Ltd.
  5. Press Releases